Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion - LARVOL DELTA

Cost-effectiveness analysis of RAD51 functional biomarker for platinum sensitivity in the GeparSixto trial (SABCS 2023) - "The pharmacological costs were calculated following treatment protocol of GeparSixto where TNBC patients received neoadjuvant paclitaxel plus Myocet®-nonpegylated liposomal doxorubicin (PM) or PM plus carboplatin (PMCb), both arms including bevacizumab. The most efficient scenarios are the functional RAD51 test and all comers. Both tBRCA1/2 and genomic HRD by Myriad Mychoice® scenarios provide worse health outcomes at a higher cost, based on the data of the GeparSixto trial. This study highlights the potential overall benefit of functional HRD biomarkers to predict PARPi sensitivity."

Biomarker • Cost effectiveness • HEOR • Breast Cancer • Triple Negative Breast Cancer • BRCA1 • BRCA2 • HRD • RAD51

Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial. (ASCO 2022) - "Investigators chose between 3 CT regimens: 4 cycles of doxorubicin/cyclophosphamide, non-pegylated liposomal doxorubicin/cyclophosphamide or docetaxel/cyclophosphamide, given q3w with G-CSF. Standard ET consisted of 5 years of aromatase inhibitor, tamoxifen or a sequence based on tolerance... In this large phase III trial, we did not find a statistically significant OS benefit with the addition of CT to ET after surgery for ER+ HER2- BC with a high GGI. Analysis of the other outcome measures will be presented."

Clinical • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - P1 | N=38 | Terminated | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2026 ➔ Jul 2026 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Jul 2026; <75% participation

Trial completion date • Trial primary completion date • Trial termination • Colorectal Cancer • Oncology • Solid Tumor • PIK3CA • PTEN

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (clinicaltrials.gov) - P1 | N=55 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Feb 2026

Platinum resistant • Platinum sensitive • Trial completion date • Trial primary completion date • Carcinosarcoma • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Sarcoma • Solid Tumor • Urothelial Cancer

Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers. (PubMed, Ann Hematol) - "These data, if validated in largest datasets with longer follow-up, suggest that treatment with NPLD could be not associated with increased BC risk in HL survivors, unlike conventional doxorubicin. Our findings provide a rationale for evaluating NPLD-based frontline therapy in prospective studies of YA&A patients with newly diagnosed HL."

Journal • Breast Cancer • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Solid Tumor

NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2027 ➔ Jun 2027

Platinum resistant • Trial completion date • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • Urothelial Cancer • BRCA1 • BRCA2 • PD-L1

Understanding the molecular insights of marketed liposomal drugs using molecular dynamics simulations of reduced scale coarse-grained models. (PubMed, NPJ Drug Discov) - "In this study, we employed coarse-grained molecular dynamics simulation to investigate the structural details of the commercially available nine liposomal formulations, with five passive loading systems (Arikayce Kit®, Visudyne®, Ambisome®, Mepact®, and Exparel®) and four active loading systems (Doxil®, Myocet®, Onivyde®, and Vyxeos®)...In four active loading systems, the presence of ions within the liposome cavity promotes the self-aggregation of drugs, thereby enhancing drug retention and release profiles. This study provided valuable molecular insights for marketed liposomes formulation."

Journal

The CARDIOPROTECT Trial (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Beth Israel Deaconess Medical Center

New P2 trial • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Transferrin-functionalized liposomes for targeted breast cancer therapy: Mechanistic insights, conjugation strategies, and translational evidence. (PubMed, Biomed Pharmacother) - "Clinically approved liposomal formulations such as Doxil® (PEGylated doxorubicin) and Myocet® (non-PEGylated doxorubicin) demonstrate improved pharmacokinetic profiles over free drug, yet rely solely on passive tumor accumulation via the enhanced permeability and retention (EPR) effect, an approach rendered insufficient by tumor heterogeneity and variable vascularization, necessitating active targeting strategies. Despite their promise, clinical translation remains constrained by TfR1 receptor saturation, off-target uptake, conjugation-induced immunogenicity, anti-PEG antibody-mediated accelerated blood clearance, and GMP-compliant manufacturing challenges. Overcoming these barriers through pharmacokinetic optimization, standardized quality control, and scalable fabrication is imperative to unlock their full therapeutic potential in breast cancer."

Journal • Review • Breast Cancer • Oncology • Solid Tumor • TFRC

Simultaneous anthracycline-based chemotherapy and dual HER2 blockade in early-stage HER2-positive breast cancer: A retrospective analysis. (ASCO 2026) - "Non-pegylated liposomal doxorubicin (Myocet) has been developed to reduce cardiotoxicity while preserving antitumor activity, offering a potential strategy for anthracycline-based approaches with an improved safety profile... In our cohort providing real world data, simultaneous anthracycline-based chemotherapy and dual HER2 blockade in early-stage HER2-positive breast cancer was an effective treatment with a pCR rate of 81,1% and excellent cardiac safety."

Retrospective data • Breast Cancer • Gynecology • Heart Failure • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Obstetrics • Oncology • Solid Tumor • HER-2

Intense dose-dense epirubicin–paclitaxel–cyclophosphamide as neoadjuvant chemotherapy (neoEPC) in high-risk ER+HER2- breast cancer: Real word experience (ESMO-BC 2026) - "Background: In patients (pts) with ER+HER2− breast cancer, neoEPC improved invasive disease-free and overall survival compared with 24 weeks of non-pegylated liposomal doxorubicin–paclitaxel (GeparOcto trial). In our series of patients with ER+/HER2− breast cancer and locally advanced disease, neoEPC was feasible, with most patients achieving a RDI ≥85%. Neurotoxicity and hematologic toxicity accounted for most dose reductions and treatment delays. The low pCR rates and the high proportion of RCB III were consistent with the initial bulky disease and luminal subtype."

Clinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

ETCTN 10563: Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: May 2026 ➔ Nov 2026 | Trial primary completion date: May 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Leiomyosarcoma • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Synovial Sarcoma • Undifferentiated Pleomorphic Sarcoma

NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2/3 | N=444 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Apr 2027

Platinum resistant • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P3 | N=579 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2026 ➔ Mar 2027

Platinum sensitive • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2026 ➔ Mar 2027

Platinum resistant • Trial completion date • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • Urothelial Cancer • BRCA1 • BRCA2 • PD-L1

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov) - P2 | N=87 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P2 trial • Platinum sensitive • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ENG • ER • HER-2 • PD-L1 • PGR

NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ Nov 2026

Platinum resistant • Trial completion date • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • Urothelial Cancer • BRCA1 • BRCA2 • PD-L1

NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P3 | N=579 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2026 ➔ Nov 2026

Platinum sensitive • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - P2/3 | N=582 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Dec 2026

Platinum resistant • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • MUC16

HIPEC: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Feb 2026 ➔ Jan 2027 | Trial primary completion date: Feb 2026 ➔ Jan 2027

Platinum resistant • Platinum sensitive • Trial completion date • Trial primary completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • Uterine Cancer

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - P1 | N=38 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Colorectal Cancer • Oncology • Solid Tumor • PIK3CA • PTEN

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: OHSU Knight Cancer Institute | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • Genito-urinary Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Sarcoma • Solid Tumor • BRCA1 • BRCA2 • HER-2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: University of Washington | Initiation date: Dec 2025 ➔ Mar 2026

Trial initiation date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ENG

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - P2/3 | N=260 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Trial completion • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor • BRAF